Founded in 2004 and headquartered in Ningbo City, Zhejiang Province, Ningbo Menovo Pharmaceutical Co., Ltd. was listed on the main board of SSE on April 7, 2017, stock abbreviation: Menovo, stock code 603538.

The company is a comprehensive international pharmaceutical science and technology manufacturing enterprise specializing in the R&D, production and sales of characteristic APIs (including intermediates) and finished drugs. It is one of the enterprises exporting the most varieties of European characteristic APIs in China and has been awarded the "top 20 CDMO enterprises in China" for many consecutive years.

The company's products cover the treatment fields of the cardiovascular, central nervous, gastrointestinal and digestive tracts. The core products Valsartan, Losartan, Clopidogrel, Perindopril, Rosuvastatin Ca, Atorvastatin Ca, Pregabalin, and other products have formed a commercialized R&D, production and sales system of the whole industrial chain.

With rigorous quality management and EHS management capabilities, high standard and large-scale production and manufacturing capacity, as well as fine and efficient teamwork, the company has established long-term deep and stable cooperation relationships with well-known domestic and foreign pharmaceutical companies. In the CDMO segmentation industry and the characteristic API segmentation industry, the company has formed a high international brand awareness and competitive advantages.

Since its listing, the company has taken advantage of the capital market, driven by the two wheels of "connotative growth + extensional expansion". While consolidating and strengthening the business of characteristic APIs, relying on continuous R&D innovation and business expansion, the company has firmly deepened the integration strategy of "pharmaceutical intermediates, APIs and preparations", expanded and extended the business of upstream intermediates and downstream preparations to further improve the layout of the industrial chain and fully expand the integration advantage;At the same time, based on its competitive advantages in the field of characteristic APIs and customer network resources, the company continued to deploy CDMO business and accelerated the building of a CDMO one-stop comprehensive service platform. By continuously improving the multi-dimensional strategic layout, taking CDMO business and preparation integration business as the core, the company actively carries out the development and commercialization of cutting-edge medical products, helps the company to "start a second business", and is committed to building Menovo into a domestic first-class, internationally renowned and highly competitive international pharmaceutical science and technology manufacturing enterprise.